Press Releases Year None202320222021202020192018201720162015201420132012 November 9, 2023 Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 1, 2023 Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023 October 24, 2023 RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting October 11, 2023 Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells October 5, 2023 RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration September 19, 2023 Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023 September 13, 2023 RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress September 11, 2023 Lineage to Present at 2023 International Spinal Research Trust Network Meeting September 6, 2023 Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics August 29, 2023 Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference August 10, 2023 Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update August 3, 2023 Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023 July 24, 2023 Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer May 22, 2023 Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index May 11, 2023 Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update May 9, 2023 Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) May 4, 2023 Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 April 26, 2023 RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration April 18, 2023 Lineage to Present at 2023 AAPS National Biotechnology Conference March 30, 2023 Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium March 20, 2023 RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit March 9, 2023 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update March 6, 2023 RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D. March 2, 2023 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 February 22, 2023 Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications February 8, 2023 Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
November 9, 2023 Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 1, 2023 Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023
October 24, 2023 RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
October 11, 2023 Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells
October 5, 2023 RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
September 19, 2023 Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
September 13, 2023 RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
September 6, 2023 Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics
August 29, 2023 Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference
August 10, 2023 Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 3, 2023 Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
July 24, 2023 Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
May 11, 2023 Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 4, 2023 Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
April 26, 2023 RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
March 30, 2023 Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium
March 20, 2023 RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
March 9, 2023 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 6, 2023 RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.
March 2, 2023 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023
February 22, 2023 Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
February 8, 2023 Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
